Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Search results for: “patient perspective”

  • FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

    FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

    By

    Regulatory Agency Perspective

    Posted: December 2018 Richard Pazdur, MD, is director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence. Below, he discusses the current status of and future directions for the FDA’s approval of oncology drugs. Q: Has the accelerated conditional approval process been a success in your view? Are there aspects you would…

  • The State of Lung Cancer in Egypt: Progress Is at Hand

    The State of Lung Cancer in Egypt: Progress Is at Hand

    By

    Global Initiatives

    By C.A.I.R.O Journal Club Executive Board Posted: December 2018 Egypt faced major turmoil in 2011, with subsequent dramatic political changes and a rapidly developing economic crises that, within a few months, led to a significant increase in the proportion of the population living below the poverty line. As per the World Bank, Egypt is defined…

  • NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

    NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

    By

    Regulatory Agency Perspective

    Posted: December 2018 Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white patients and identified molecular differences that may result in population differences in tumor biology. Researchers led by Brid M. Ryan, PhD, MPH, an investigator from the Laboratory of Human Carcinogenesis…

  • Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

    Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

    By

    Meeting News

    By Edgardo S. Santos Castillero, MD, FACP Posted: December 2018 Five abstracts were presented at the Presidential Symposium of the 2018 IASLC Latin America Conference on Lung Cancer, held in August in Córdoba, Argentina. All of the presentations centered on immunotherapy, with the following themes: (1) defining best treatment options as first-line therapy, (2) novel…

  • After the Consultation: Social Media, Inter-Patient Communication, and Clinical Trials

    After the Consultation: Social Media, Inter-Patient Communication, and Clinical Trials

    By

    Patient Advocacy & Survivorship

    By D. R. Camidge Posted: October 2018 Between March 2017 and April 2018, nearly 20,000 new members signed up for the Lung Cancer Survivors Support Community on Inspire. At present, membership of this online community is over 90,000 individuals from more than 200 different countries. Physicians have always known that patients continue discussions with friends…

  • EGFR TKIs: A Marathon or Sprint?

    EGFR TKIs: A Marathon or Sprint?

    By

    Evolving Standards of Care

    By Edgardo S. Santos Castillero, MD, FACP Posted: October 2018 The approval of osimertinib in the frontline setting for patients with EGFR-sensitizing mutations has immediately challenged the decision-making process for oncologists. Osimertinib, a third-generation EGFR TKI, was initially developed as a specific therapy for EGFR T790M mutations, the most common mechanism of acquired resistance for…

  • NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

    NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

    By

    Regulatory Agency Perspective

    Posted: August 2018 In October 2017, the United States National Cancer Institute (NCI) launched a major effort to expand the discovery and validation of predictive biomarkers on cancer immunotherapy. This $56.3-million NCI initiative is part of the U.S. Cancer Moonshot, launched by former President Barack Obama and Vice President Joe Biden and funded by the…

  • The Budget Landscape with Dr. Douglas R. Lowy

    The Budget Landscape with Dr. Douglas R. Lowy

    By

    Regulatory Agency Perspective

    By Erik MacLaren, PhD Posted: August 2018 The National Cancer Institute (NCI) and researchers who rely on the funding it provides have spent much of the past year under the shadow of expected cuts in federal funding. President Trump’s budget request last year proposed cutting the National Institutes of Health (NIH) budget overall by $7.7…

  • Global Insights on New Clinical Practice Guideline for the Treatment of Malignant Pleural Mesothelioma

    Global Insights on New Clinical Practice Guideline for the Treatment of Malignant Pleural Mesothelioma

    By

    Evolving Standards of Care

    By Hedy L. Kindler, MD Posted: August 2018 The American Society of Clinical Oncology (ASCO) has issued its first-ever clinical practice guidelines on the management of patients with malignant pleural mesothelioma (MPM), based on a systematic review of the medical literature.1 This comprehensive guideline consists of 63 recommendations on the diagnosis, staging, chemotherapy treatment, surgical…

  • Israel's Parliament Hosts IASLC CEO Dr. Fred R. Hirsch

    Israel's Parliament Hosts IASLC CEO Dr. Fred R. Hirsch

    By

    Global Initiatives

    By Shani Shilo, DMD, PhD, andNir Peled, MD, PhD, FCCP Posted: June 2018 On March 6, 2018, the Israeli parliament, the Knesset, held a Science and Technology Committee meeting devoted to lung cancer, new technologies, and their effects on the future of care. The meeting was an initiative of the Israel Lung Cancer Foundation and…

View ILCN Archives

Provider Resources

Popular Articles